论文部分内容阅读
目的探讨阿立哌唑治疗舒必利所致高催乳素血症的疗效及安全性。方法60例男性、80例女性舒必利所致高催乳素血症患者,分别随机分为治疗组、对照组(男性:治疗组、对照组各30例;女性:治疗组、对照组各40例)。维持舒必利治疗不变,分别加用阿立哌唑(5mg)、维生素C治疗,疗程6周。于治疗前和6周末检测催乳素(PRL);评定简明精神病量表(BPRS)、不良反应量表。结果6周末,治疗组男、女性PRL分别为(21.5±6.4)和(26.9±7.1)μg·L-1,较基线(84.8±15.9)和(136.5±38.2)μg·L-1下降,差异有极显著性(均P<0.01);对照组男、女性PRL分别为(79.3±15.5)和(122.8±34.0)μg·L-1,与基线(85.1±16.7)和(129.8±37.9)μg·L-1比较差异无显著性(均P>0.05)。治疗组男、女性PRL的下降率分别为(74.7±5.9)%和(78.3±9.5)%,高于对照组PRL的下降率[分别为(6.5±5.8)%,(4.9±4.3)%](均P<0.01)。治疗组和对照组男、女性BPRS评分与基线的差异均无显著性(均P>0.05);两组总体不良反应发生率相近(P>0.05)。结论阿立哌唑治疗舒必利所致男、女性高催乳血症有效、安全。
Objective To investigate the efficacy and safety of aripiprazole in the treatment of hyperprolactinemia induced by sulpiride. Methods Sixty male and 80 female patients with hyperprolactinemia were randomly divided into treatment group and control group (male: treatment group and control group: 30 cases each; female: treatment group and control group: 40 cases each) . To maintain the same treatment of sulpiride, were added with aripiprazole (5mg), vitamin C treatment for 6 weeks. Prolactin (PRL) was measured before treatment and at the end of 6 weeks; BPRS and ADR were assessed. Results At 6 weeks, the PRL of male and female in treatment group were (21.5 ± 6.4) and (26.9 ± 7.1) μg · L -1, respectively, which were significantly lower than those of baseline (84.8 ± 15.9) and (136.5 ± 38.2) μg · L -1 (79.3 ± 15.5) and (122.8 ± 34.0) μg · L-1 in the control group were significantly higher than those in the baseline (85.1 ± 16.7 and 129.8 ± 37.9) μg / L, respectively · L-1 was no significant difference (all P> 0.05). The declining rates of PRL in male and female patients in the treatment group were (74.7 ± 5.9)% and (78.3 ± 9.5)%, respectively, which were higher than those in the control group (6.5 ± 5.8% and 4.9 ± 4.3%, respectively) (All P <0.01). There was no significant difference between the BPRS score and the baseline in the treatment group and the control group (P> 0.05). The incidence of adverse reactions in the two groups was similar (P> 0.05). Conclusion Aripiprazole is effective and safe for the treatment of hyperprolactinemia in both male and female patients due to sulpiride.